PhaseWell Research, a multisite clinical research company headquartered in Nashville, Tennessee, announced it has acquired Chase Medical Research, a Connecticut-based clinical research site with locations in Waterbury and Hamden.
The acquisition strengthens PhaseWell’s presence in the Northeast and enhances its ability to support cardiometabolic and central nervous system clinical research within community-based settings. Chase Medical Research brings more than 20 years of experience conducting trials across a wide range of therapeutic areas, including metabolic and endocrine disorders, cardiovascular disease, central nervous system conditions, respiratory and vaccine research, pain and musculoskeletal disorders, gastrointestinal and urologic conditions, and men’s and women’s health.
Led by founder and principal investigator Dr. Joseph Soufer, Chase Medical Research has developed a reputation for strong patient retention, high-quality data, and patient-centered operations. The organization’s access to a diverse patient population in Connecticut is expected to further strengthen PhaseWell’s research capabilities.
The transaction aligns with PhaseWell’s broader strategy of building a national network of trusted research sites capable of supporting Phase I through Phase IV clinical trials across high-demand therapeutic areas such as oncology, central nervous system disorders, and cardiometabolic conditions. Collectively, PhaseWell’s sites have completed more than 2,200 clinical trials and contributed to the development and approval of more than 185 therapies.
With this acquisition, PhaseWell aims to expand access to clinical trials in local communities while leveraging Chase Medical Research’s expertise to enhance its national platform. The partnership is also expected to create additional opportunities for patients in Connecticut to participate in innovative clinical studies.
Quadriga Partners served as the exclusive financial advisor to Chase Medical Research in connection with the transaction.
KEY QUOTES:
“Chase Medical Research’s 20+ years driving advances within cardiometabolic research exemplifies the type of community-based research sites we seek to partner with… their 20+ years of driving advances within cardiometabolic research as a primary focus stands out within our industry, and their successes with pharma partners and community patients are testament to the strengths we are acquiring in this partnership.”
Carsten Bick, Chief Executive Officer, PhaseWell Research
“We look forward to this next chapter with PhaseWell. The partnership allows us to grow our sites and extend our reach while staying grounded in the Connecticut communities we serve. We are creating more opportunities to bring innovative clinical trials to patients in Connecticut while taking Chase Medical’s expertise outside our four walls to bring best-in-class cardiometabolic capabilities across PhaseWell’s growing national presence.”
Dr. Joseph Soufer, Founder And Lead Principal Investigator, Chase Medical Research
